ARS Pharmaceuticals, Inc. SPRY Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s accretion (amortization) of discounts and premiums, investments?
- ARS Pharmaceuticals, Inc. (SPRY) reported accretion (amortization) of discounts and premiums, investments of $990K in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
- ARS Pharmaceuticals, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 49.5% year-over-year, from $1.96M to $990K.
- What does accretion (amortization) of discounts and premiums, investments mean?
- Reflects the non-cash adjustment to the carrying value of investment securities to account for the amortization of premiums or the accretion of discounts over the life of the instrument. This adjustment aligns the investment's book value with its effective interest yield, providing a clearer picture of the actual interest income earned on the portfolio.